Avicanna (AVCN) AI Stock Analysis

• Market Cap: C$23.25M
• Dividend Yield: N/A
• Average Volume (3M): 55.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: 2.41%
• EPS Growth: 74.61%
• Country: CA
• Employees: 87
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 125,683,370
• 10 Day Avg. Volume: 77,161
• 30 Day Avg. Volume: 55,794
• PEG Ratio: 0.13
• Price to Book (P/B): 13.19
• Price to Sales (P/S): 1.20
• P/FCF Ratio: -10.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.19 ▼(-13.18% Downside)
• Action: Reiterated Date: 01/04/26
• Date: Action: Reiterated 01/04/26

The score is held back primarily by continued losses and negative cash flow despite strong revenue growth and improving gross margins, plus a weak technical trend (price below major moving averages and negative MACD). Valuation also screens poorly due to the negative P/E, consistent with the lack of current profitability.

Positive Factors

Revenue Growth

Nearly 48% TTM revenue growth indicates accelerating market adoption of Avicanna’s cannabinoid product lines and B2B services. Sustained top-line expansion supports scale benefits, helps absorb fixed costs, and creates durable optionality to fund R&D and commercial expansion over the next several quarters.

Margin Improvement

A jump to ~52% gross margin from ~40% suggests structural improvement in product mix, higher-value formulations, or pricing power tied to IP and formulation capabilities. Higher durable gross margins increase the potential to convert revenue scale into lasting operating profitability as overhead is leveraged.

Cleaner Balance Sheet

A positive equity position and reported zero debt materially lower solvency risk and interest burden. This improved financial flexibility supports strategic partnerships, manufacturing investments and R&D without immediate refinancing pressure, aiding medium-term operational stability.

Negative Factors

Negative Cash Flow & Profitability

Margins remain negative (~-7%) and the company is still a net cash user, with TTM operating and free cash flow deficits. Persistent cash burn constrains reinvestment in commercialization and R&D, increases dependency on external capital, and delays the timeline for sustained, internally financed profitability.

Weak Returns / Small Equity Cushion

Although equity is positive, its modest size and negative ROE show invested capital hasn’t produced returns yet. A thin equity base provides limited buffer against further losses or large investments, raising vulnerability to shocks and constraining the company’s ability to fund growth without dilutive financing.

Reliance on External Financing

The pack explicitly notes the business is not self-funding and will likely need external financing or material cost/revenue improvements. Dependence on outside capital increases execution risk, potential shareholder dilution, and sensitivity to capital-market conditions over the medium term.

Avicanna Business Overview & Revenue Model

Company Description

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

How the Company Makes Money

Avicanna generates revenue through multiple key streams, including the sale of its proprietary cannabinoid formulations and products to healthcare providers and retailers. The company's revenue model is bolstered by its partnerships with other organizations in the cannabis and pharmaceutical sectors, which facilitate product development and expansion into new markets. Additionally, Avicanna may benefit from licensing agreements for its technologies and formulations, providing a supplemental income source. The company also engages in research collaborations that can lead to financial support and shared revenue from product sales, further enhancing its revenue potential.

Avicanna Financial Statement Overview

Summary

Revenue is growing strongly (~+48% TTM) and gross margin has improved (~52% TTM vs ~40% in 2023), with a cleaner balance sheet (positive equity and $0 debt). However, profitability and cash generation remain weak: EBIT and net margins are still negative (~-7% each) and operating/free cash flow are negative (about -$1.2M / -$1.8M TTM).

Income Statement

TTM (Trailing-Twelve-Months) revenue is $25.5M with strong growth versus the prior year (about +48%), and gross margin has improved meaningfully over time (about 52% TTM vs ~40% in 2023). However, profitability is still negative: TTM operating results remain in the red (EBIT margin ~-7%) and net margin is also negative (~-7%), indicating the business has not yet converted scale and higher gross profit into sustainable earnings.

Balance Sheet

The balance sheet shows a notable cleanup versus prior years: stockholders’ equity has turned positive (about $3.1M TTM vs negative in 2022–2023), and total debt is reported at $0 in TTM (down from modest debt in 2024 and higher levels earlier). The main weakness is returns: equity is positive but still generating losses (return on equity remains negative TTM), and the equity base is relatively small versus total assets, leaving less cushion if losses persist.

Cash Flow

Cash generation remains a key pressure point. TTM operating cash flow is negative (about -$1.2M) and free cash flow is also negative (about -$1.8M), meaning the company is still consuming cash to operate and invest. The improvement versus 2024 is a positive signal (less cash burn year-over-year), but the business is not yet self-funding and would likely remain dependent on external financing or further cost/revenue improvements to reach sustained positive cash flow.

Breakdown	TTM	Dec 2024	Mar 2024	Dec 2022	Mar 2022	Jun 2021
Income Statement
Total Revenue	25.50M	25.46M	16.79M	4.05M	3.27M	1.57M
Gross Profit	13.33M	12.90M	6.66M	1.11M	2.83M	-570.00K
EBITDA	-1.05M	-2.43M	-7.36M	-12.18M	-15.13M	-33.70M
Net Income	-1.88M	-3.62M	-8.74M	-14.73M	-16.77M	-32.86M
Balance Sheet
Total Assets	21.17M	20.12M	21.97M	17.62M	22.30M	30.16M
Cash, Cash Equivalents and Short-Term Investments	464.85K	448.03K	477.20K	1.19M	31.00K	2.52M
Total Debt	0.00	109.23K	1.80M	3.21M	1.66M	1.94M
Total Liabilities	9.47M	10.38M	14.00M	14.16M	15.39M	16.25M
Stockholders Equity	3.11M	2.31M	-112.50K	-383.56K	1.15M	6.02M
Cash Flow
Free Cash Flow	-1.79M	-2.95M	-1.96M	-7.50M	-12.45M	-15.43M
Operating Cash Flow	-1.23M	-2.55M	-1.40M	-7.44M	-11.66M	-13.97M
Investing Cash Flow	-554.06K	-402.57K	-3.05M	810.24K	760.83K	-2.71M
Financing Cash Flow	1.63M	3.41M	3.55M	9.90M	10.06M	17.39M

Avicanna Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCN, the sentiment is Neutral. The current price of 0.22 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.20, and below the 200-day MA of 0.24, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.94 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:AVCN.

Avicanna Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CWEB	51 Neutral	C$162.61M	-1.15	-109.83%	―	-4.23%	37.33%
AVCN	46 Neutral	C$23.25M	-5.08	-68.32%	―	2.41%	74.61%
CRDL	46 Neutral	C$145.18M	-3.21	-218.48%	―	―	21.17%
INNO	46 Neutral	C$26.54M	-6.72	-71.80%	―	-3.94%	-17.62%
LABS	45 Neutral	C$27.35M	-3.68	-19.10%	―	18.06%	34.58%
PCLO	44 Neutral	C$8.46M	5.19	―	―	15.64%	58.47%

Avicanna Corporate Events

Avicanna Publishes Real-World Evidence Showing Pain and Quality-of-Life Gains With Medical Cannabis

Avicanna has announced the first peer-reviewed publication from its Medical Cannabis Real-World Evidence (MCRWE) program, reporting results of a prospective observational study of physician-authorized medical cannabis for chronic pain, conducted through its MyMedi.ca platform and led by University Health Network’s Dr. Hance Clarke. The study, published in the Canadian Journal of Pain, found statistically significant improvements over 24 weeks in pain interference, pain intensity, anxiety, depressive symptoms and quality of life among patients who continued treatment, though changes did not reach minimal clinically important thresholds, underscoring the need for further randomized, placebo-controlled trials; Avicanna’s ongoing role in providing infrastructure and support for large-scale real-world evidence positions the company as an important contributor to clinical data generation in the evolving medical cannabis field.

The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.

Avicanna Strengthens Board with Appointment of Capital Markets Veteran Michael Kott

Avicanna Inc. announced a board transition with the resignation of director Paul Fornazzari and the appointment of seasoned capital markets executive and long-time shareholder Michael Kott to its board, effective January 1, 2026. Kott, founder and CEO of CM-Equity AG and now head of a global single-family office, brings more than three decades of experience in international capital markets, governance and cross-border investments, which the company’s leadership expects will support its next stage of growth, scaling efforts and value creation for shareholders amid growing global momentum for evidence-based cannabinoid pharmaceuticals.

The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.22 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.

Avicanna Backs U.S. Cannabis Reclassification as It Advances 2025 Clinical and R&D Programs

Avicanna has endorsed the U.S. administration’s executive order to reclassify cannabis to a less restrictive category, arguing that the shift aligns with its evidence-based approach to cannabinoid medicines and could unlock greater clinical research, innovation, investment and, over time, reimbursement and patient access for rigorously validated therapies. The company also reported 2025 scientific and medical progress, including advancing a large real-world evidence study with University Health Network and initiating a Phase II trial in arthritic pain, expanding its pre-clinical and product pipeline with a new U.S. patent and commercialization of technologies such as PwdRx to enhance its Rho Phyto portfolio, and broadening medical affairs activities through education, collaborations and its MyMedi.ca platform to improve patient support, clinical guidance and insurance coverage.

The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.22 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.

Avicanna Advances Cannabinoid Delivery with Novel PwdRx Platform

Avicanna announced positive preclinical results and a provisional patent application for its novel Powder Drug Delivery System (PwdRx) platform, which enhances the bioavailability and absorption of cannabinoids. This advancement addresses formulation challenges associated with cannabinoids and offers potential new pharmaceutical and commercial opportunities, reinforcing Avicanna’s leadership in cannabinoid science and technology.

The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.

Avicanna Reports Q3 2025 Growth and Strategic Advances

Avicanna Inc. reported its Q3 2025 financial results, highlighting continued revenue growth in Canada and internationally, driven by medical affairs initiatives and commercial advancements. Despite facing short-term margin pressures, the company remains optimistic about achieving sustainable profitability. Key developments include a significant increase in Canadian sales, the issuance of a U.S. patent for a topical cannabinoid composition, and the first export of organic certified cannabis flower to Switzerland. Additionally, Avicanna launched the re+PLAY CBD wellness brand in the U.S., showcasing its proprietary formulations.

The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.